SAMSUNG-BIOEPIS
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Imraldi® , a biosimilar referencing Humira® 1 (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis and uveitis.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170824006317/en/
With the EC’s marketing authorization of Imraldi® , Samsung Bioepis becomes the industry’s first to receive European approvals for biosimilars referencing all three anti-TNF-α blockbusters. Benepali® (etanercept) and Flixabi® (infliximab) received EC marketing authorization in January 2016 and May 2016, respectively.
“We are proud to become the industry’s first to obtain European approval for a third TNF inhibitor. This is a testament to our agile biologics development platform, which has allowed us to develop approved biosimilars in less time at lower cost,” said Christopher Hansung Ko, President & CEO of Samsung Bioepis. “Through relentless process innovation and an uncompromising commitment to quality, we remain dedicated to advancing one of the industry's strongest biosimilar pipelines, so that more patients and healthcare systems across Europe will benefit from biosimilars.”
The EC approval of Imraldi® applies to all 28 European Union (EU) member states as well as the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. Biogen will commercialize Imraldi® in the EU and EEA member states.
The EC approval of Imraldi® follows a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in June 2017.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six first-wave candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com .
1 Humira ® is a registered trademark of AbbVie Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170824006317/en/
Contact:
Samsung Bioepis Co., Ltd.
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options4.6.2025 20:19:00 CEST | Press release
The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast and lung cancer and active brain metastases, and leptomeningeal disease from solid tumors. These results were presented as an oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, with select results simultaneously published in Nature Medicine. MEDSIR’s DEMETHER clinical trial was mentioned during abstract discussion due to the relevance of its strategy. Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious compli
QPS Celebrates 30th Anniversary4.6.2025 18:00:00 CEST | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604778675/en/ Dr. Benjamin Chien founder and CEO of QPS Holdings, LLC. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a globa
Cessna SkyCourier Combi Configuration Achieves Certification From the National Civil Aviation Agency of Brazil4.6.2025 17:30:00 CEST | Press release
Cleiton Táxi Aéreotakes first delivery in South America for charter operations The Cessna SkyCourier Combi configuration kit recently achieved certification from the National Civil Aviation Agency of Brazil (ANAC) and joined the fleet of Brazilian charter company Cleiton Táxi Aéreo (CTA). This marks the first delivery of the SkyCourier into South America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604928791/en/ The Cessna SkyCourier Combi configuration kit recently achieved certification from the National Civil Aviation Agency of Brazil (ANAC) and joined the fleet of Brazilian charter company Cleiton Táxi Aéreo (CTA). This marks the first delivery of the SkyCourier into South America. (Photo credit: Textron Aviation) The Cessna SkyCourier is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. CTA recently took delivery of a passenger variant of the twin-engine, large-utility turbopr
IFF Unveils Game-Changing Outlook on GLP-1 Consumers4.6.2025 17:00:00 CEST | Press release
New research reveals how food and beverage brands can lead innovation for millions facing sensory and nutritional challenges IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is reshaping the sensory experience and nutritional needs associated with eating and drinking. The report outlines how food and beverage manufacturers can better support this emerging consumer segment with products that align with their evolving preferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604818126/en/ “IFF is empowering our customers to lead the next wave of food and beverage innovations beyond traditional formulations, including helping GLP-1 consumers have choices they desire,” said Erik Fyrwald, IFF CEO. “We aim to bring back the joy of eating and drinking by offering more healthy, great-tasting nutrition choices for all
Visa Cash App Racing Bulls (VCARB) Formula One™ Team Accelerates Racing Car Design with Neural Concept’s Engineering AI4.6.2025 16:04:00 CEST | Press release
Visa Cash App Racing Bulls Formula One™Team has deployed Neural Concept, the world’s leading AI platform for engineering design to accelerate the team’s car design and optimize aerodynamic performance through AI-powered, data-driven engineering workflows that enable faster design iteration and better-informed decisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603592297/en/ Visa Cash App Red Bull - Racing Bulls and Neural Concept AI F1 vehicle partnership Neural Concept’s proprietary Engineering AI platform complements traditional Computational Fluid Dynamics (CFD) with high-speed predictive simulations. Engineers can use digital twins to evaluate thousands of design variants across complex “multi-physics” environments that mimic real-world track conditions such as wind and temperature differences. This enables VCARB to explore more designs, unlocking new performance gains within every iteration. Laurent Mekies, Tea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom